Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q1 2023 (← Previous) (Next →)

Filing Date: May 11, 2023

Total Value ($000): $47,973 (100.0% shares, 0.0% debt)

Holdings (7)

CRSP CRISPR Therapeutics AG 47.0%

Value ($000) $22,550 Shares 498,558 Est. Cost $40.26 Unrealized +20.6%

— Gritstone Oncology, Inc. 20.6%

Value ($000) $9,900 Shares 3,561,150 Est. Cost $7767.86 Unrealized —

— Passage Bio, Inc. 9.9%

Value ($000) $4,750 Shares 4,959,769 Est. Cost $17.48 Unrealized —

— CymaBay Therapeutics, Inc. 9.9%

Value ($000) $4,742 Shares 543,753 Est. Cost $9871.60 Unrealized —

— Adverum Biotechnologies, Inc. 7.6%

Value ($000) $3,636 Shares 5,068,233 Est. Cost $9646.10 Unrealized —

— Aligos Therapeutics, Inc. 4.2%

Value ($000) $2,028 Shares 2,320,381 Est. Cost $27.65 Unrealized —

— Minerva Surgical Inc. 0.8%

Value ($000) $367 Shares 1,673,700 Est. Cost $5.14 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	498,558	$22,550	47.0%	$40.26	+20.6%	Common Shares	H17182108
—	Gritstone Oncology, Inc.	3,561,150	$9,900	20.6%	$7767.86	—	Common Stock	39868T105
—	Passage Bio, Inc.	4,959,769	$4,750	9.9%	$17.48	—	Common Stock	702712100
—	CymaBay Therapeutics, Inc.	543,753	$4,742	9.9%	$9871.60	—	Common Stock	23257D103
—	Adverum Biotechnologies, Inc.	5,068,233	$3,636	7.6%	$9646.10	—	Common Stock	00773U108
—	Aligos Therapeutics, Inc.	2,320,381	$2,028	4.2%	$27.65	—	Common Stock	01626L105
—	Minerva Surgical Inc.	1,673,700	$367	0.8%	$5.14	—	Common Stock	60343F106